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Abstract 
Purpose: Vesicular glutamate transporters (VGLUTs), essential for loading 
glutamate into synaptic vesicles, are present in various neuronal systems. 
However, the expression of VGLUTs in neurons innervating the urinary bladder 
has not yet been analyzed. Here, we study the presence of VGLUTs type-1, -2 and 
-3 (VGLUT1, VGLUT2 and VGLUT3, respectively) in mouse urinary bladder 
neurons. Materials and Methods: Expression of VGLUT1, VGLUT2 and calcitonin 
gene-related peptide (CGRP) was analyzed by immunohistochemistry in 
retrogradely labeled primary afferent and autonomic neurons of BALB/C mice after 
injecting Fast Blue in the urinary bladder wall. To study VGLUT3, retrograde 
tracing of the urinary bladder was performed in transgenic mice where VGLUT3 is 
identified by detection of enhanced green fluorescent protein (EGFP). Results: 
Most urinary bladder DRG neurons expressed VGLUT2. A smaller percentage of 
neurons also expressed VGLUT1 or VGLUT3. Coexpression with CGRP was only 
observed for VGLUT2. Occasional VGLUT2-immunoreactive (IR) neurons were 
seen in the major pelvic ganglion (MPG). Abundant VGLUT2-IR nerves were 
detected in the urinary bladder dome, trigone and also the urethra; VGLUT1-IR 
nerves were discretely present. Conclusions: We present novel data on the 
expression of VGLUTs in sensory and autonomic neurons innervating the mouse 
urinary bladder. The frequent association of VGLUT2 and CGRP in sensory 
neurons suggests interactions between glutamatergic and peptidergic 
neurotransmissions, potentially influencing commonly perceived sensations in the 
urinary bladder, such as discomfort and pain.
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Abbreviations and Acronyms: 
CGRP, calcitonin gene-related peptide; DRG, dorsal root ganglion; eGFP, 
enhanced green fluorescent protein; FB, fast blue; IR, immunoreactive; Li, like-
immunoreactivity; LS, lumbosacral; LSC, lumbar sympathetic chain; MPG, major 
pelvic ganglion; NPs, neuron profiles; TL, thoracolumbar; TRPV1, transient 
receptor potential cation channel, subfamily V, member 1; VGLUTs, vesicular 
glutamate transporters 
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The urinary bladder is profusely innervated by sympathetic, parasympathetic and 
also primary afferent neurons 1,2. The main neurotransmitters involved in 
autonomic functions are noradrenaline and acetylcholine, produced by 
sympathetic and parasympathetic neurons, respectively. Presence of these 
neurotransmitters in neurons and nerve fibers is usually shown by identification of 
associated molecules such as tyrosine hydroxylase (TH) or the norepinephrine 
transporter-1 (noradrenergic) and choline acetyltransferase or the vesicular 
acetylcholine transporter (acetylcholinergic). Visceral primary afferent neurons, like 
non-visceral ones 3, are classically described as being glutamatergic and often 
capable of coexpressing a variety of molecules, including neuropeptides, various 
kinds of receptors (see 4) and even markers of autonomic neurons (TH 5). 
The earliest morphological demonstration of the glutamatergic nature 
of urinary bladder dorsal root ganglion (DRG) neurons was published over 12 
years ago, when Keast and Stephenson 6 reported immunohistochemically 
detectable glutamate in approximately 50% of rat urinary bladder DRG neurons. 
For its use in neurotransmission, glutamate is taken up into synaptic vesicles by 
means of vesicular glutamate transporters (VGLUTs). Different types of VGLUTs 
have been recently identified, resulting in the reliable immunohistochemical 
characterization of various subpopulations of glutamatergic neurons, both in the 
central and the peripheral nervous systems 7. In the latter, VGLUTs have been 
characterized in rodent non-visceral (see 8 and references therein) and colorectal 
primary afferent neurons 9, as well as in some lumbar sympathetic chain (LSC) 
neurons after peripheral nerve injury 10. 
To date, analysis of the presence of VGLUTs in DRG and autonomic 
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neurons projecting to the urinary bladder is not available. Here, we present a 
comprehensive immunohistochemical study of the expression of the three known 
VGLUTs in DRG, LSC and major pelvic ganglion (MPG) neurons innervating the 
mouse urinary bladder. 
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MATERIALS AND METHODS 
Male BALB/c (Taconic, Germantown, NJ, USA; 7-8 weeks old) and 
129S6/SvEvTac-C57Bl/6 mice (11; 6 weeks old) were used in all experiments. All 
research protocols adhered to the Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care Use Committee of the 
Universities of Pittsburgh and California in San Francisco. 
Of all commercial antibodies against VGLUT3 currently available, none 
efficiently label DRG neurons. Therefore, we also utilized a transgenic mouse 
expressing EGFP under the control of VGLUT3 regulatory sequences that reliably 
identify VGLUT3 expressing neurons in these mice (see 11). 
The urinary bladders of five BALB/c male mice, and three VGLUT3-
EGFP male mice, 6 weeks old, were injected with the fluorescent retrograde 
neuronal tracer Fast Blue (FB, 2% in saline; EMS-Chemie, Gross Umstadt, 
Germany) according to previously reported surgical procedures (see 9). 
  Twelve days after injection of FB, mice were deeply anaesthetized 
using sodium pentobarbital (60 mg/kg, i.p.; Ovation Pharmaceuticals, Deerfield, IL, 
USA) and perfused via the ascending aorta with previously described fixative 
mixtures (see 9). Three naïve BALB/C mice were similarly anesthetized and 
perfused. Thoracolumbar (T8-L1; TL) and lumbosacral (L6-S2; LS) DRGs, MPG, 
LSC and urinary bladder were dissected out and processed following previously 
described immunohistochemistry protocols (see 8,9). Table 1 lists all antibodies 
used. Further details on these antibodies can be found in previous publications 
(see 9 and references therein). 
Single- or double-staining experiments, utilizing tyramide signal 
amplification (TSA plus, NEN Life Science Products, Inc., Boston, MA, USA) 
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and/or indirect immunofluorescence techniques, were performed (see 9). Briefly, 
sections were incubated with one or two antibodies, for single or double staining, 
respectively, and processed first following the TSA technique. Additional TSA or 
indirect immunofluorescence protocols were employed for double staining 
experiments. Nonspecific staining by the secondary antibody was tested in a few 
sections by omission of the primary antibody. CGRP, VGLUTs and EGFP antisera 
have been thoroughly characterized in previous publications (see 8,9 and 
references therein). 
  Immunofluorescence sections were examined on a Nikon Eclipse 
E600 microscope (Nikon, Tokyo, Japan) provided with a Retiga 2000 R Fast CCD 
camera (Q-Imaging, Surrey, British Columbia, Canada) using IPLab software 
(Scanalytics Inc., Vancouver, Canada). Colocalization analysis was done using a 
Fluoview FV 1000 confocal microscope (Olympus, Tokyo, Japan). Resolution, 
brightness and contrast of the images were optimized using Adobe Photoshop 
CS3 software (Adobe Systems Inc., San Jose, CA). Because confocal imaging of 
FB was not possible due to lack of appropriate filters, some images (MPG) were 
composed by merging separate optical (FB) and confocal (other markers of 
interest) photomicrographs. 
Retrogradely traced neuron profiles (NPs) were quantified in every 
fifth section of TL and LS DRGs (5-8 sections/ganglion). Percentages of VGLUT-
expressing urinary bladder NPs were obtained by comparing the total number of 
FB-positive urinary bladder vs. those expressing each marker. Cell body diameters 
of a representative sample of each type of quantified NP (more than 7 and up to 
48 neurons per type) were measured using the public domain NIH program, Image 
J (http://rsb.info.nih.gov/ij/download.html), and these data used to correct the raw 
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counts, based on the Abercrombie correction factor 12. Only NPs exhibiting an 
intensity of immunostaining higher than 2 orders of magnitude were counted. 
  Data are presented as mean  SEM and were statistically analyzed 
using the Student’s t-test for independent samples; P<0.05 was considered 
significant. 
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RESULTS 
Retrograde tracing from the urinary bladder revealed a discrete number of FB-
positive NPs of different sizes per section in TL and LS DRGs that were easily 
differentiated from FB-negative NPs (Figs. 1, 2). 
 All VGLUTs were expressed in mouse DRG neurons projecting to the 
urinary bladder, although in different proportions (Table 2; Fig. 1). On average, 
32.4 ± 3.6%, 94.1 ± 3.0% and 18.1 ± 1.3% of urinary bladder DRG NPs expressed 
VGLUT1, VGLUT2 or eGFP-VGLUT3, respectively. Further analysis showed that 
the expression of VGLUTs differed between TL and LS DRGs. VGLUT1 was 
present in a greater proportion of TL (38.9 ± 4.2%) than LS (25.9 ± 3.6%) urinary 
bladder DRG NPs (P<0.05; Table 2; Fig. 1A-C); the majority of VGLUT1-IR NPs 
appeared to be medium- to large-sized (Fig. 1A-C). VGLUT2 was detected in 
similar, high proportions in TL (93.8 ± 2.0%) and LS (94.3 ± 4.1%) urinary bladder 
DRG NPs of all sizes (Table 2; Fig. 1D-I); occasional urinary bladder DRG neurons 
lacking VGLUT2 were also found (Fig. 1G-I). eGFP-VGLUT3 was expressed in a 
greater proportion of TL (27.9 ± 2.0%) than LS (8.3 ± 0.6%) urinary bladder DRG 
NPs of small size, respectively (P<0.01; Table 2; Fig. 1J-L). Finally, in addition to 
urinary bladder neurons, abundant VGLUT2- or eGFP-VGLUT3-IR, and several 
VGLUT1-IR, FB-negative neurons were detected in all DRGs (Figs. 1, 2). 
 Colocalization analysis showed that only VGLUT2 coexpressed with 
CGRP in urinary bladder DRG NPs (Fig. 2). Thus, while no VGLUT1 urinary 
bladder DRG NPs coexpressed CGRP (Fig. 2A-D), 54.7 ± 3.4% of TL and 52.2 ± 
9.9% of LS urinary bladder DRG NPs coexpressed VGLUT2 and CGRP (Fig. 2E-
H). FB-negative VGLUT2-IR NPs coexpressing CGRP (Fig. 2F-H) or CGRP-only 
urinary bladder DRG neurons were also detected (Fig. 2A-D; I-L). As observed for 
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VGLUT1, virtually no eGFP-VGLUT3 urinary bladder DRG NPs coexpressed 
CGRP (Fig. 2I-L). Such lack of coexpression with CGRP was also noted for FB-
negative VGLUT1- (Fig. 2A-D) or eGFP-VGLUT3-IR NPs (Fig. 2I-L). 
 Retrograde labeling of LSC (Fig. 3A, D) and MPG neurons (Fig. 3G, J. M. 
P) from the urinary bladder was also noted. In the LSC, no FB-positive neurons 
expressed VGLUT1 or VGLUT2 (Fig. 3A-C and Fig. 3D-F, respectively). 
Nevertheless, some VGLUT2-IR fibers, and what appeared to be VGLUT2-IR 
synaptic varicosities, were detected in the LSC (Fig. 3D-F). Similarly, FB-positive 
neurons in the MPG also lacked VGLUT1-like immunoreactivity (Li) (Fig. 3G-I), 
which was only associated with a few varicose profiles (Fig. 3H, I). In contrast, 
occasional VGLUT2-IR urinary bladder MPG neurons were found (Fig. 3J-L), along 
with many VGLUT2-IR fibers and varicosities (Fig. 3K, L, N, O, Q, R). Some of 
these varicosities exhibited a basket-like appearance, surrounding non-urinary 
bladder MPG (Fig. 3P-R) neurons. 
 In the urinary bladder, VGLUT1-Li was commonly observed in the 
muscular (Fig. 4A) and, to a lesser extent, in the submucosal layers (Fig. 4B) of 
the organ. In comparison, VGLUT2-IR nerves formed a profuse fiber network 
spanning all layers of the urinary bladder wall throughout the dome (Fig. 4C, D), 
trigone (Fig. 4E) and the urethra (Fig. 4F, G). Colocalization analysis showed that 
VGLUT1 and CGRP coexpression in urinary bladder nerve fibers was virtually 
nonexistent (Fig. 5A-C). In contrast, VGLUT2 and CGRP were often colocalized in 
nerve fibers in the urinary bladder (Fig. 5D-L). 
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DISCUSSION 
Although it is well established that sensory neurons are often glutamatergic 
6, information on the types of VGLUTs involved in the synaptic vesicle 
uptake of glutamate in such neurons is only recently receiving attention (see 
8). Evidence for the expression of VGLUTs in visceral sensory neurons was 
first reported by Tong et al. 13, in ganglia innervating the rat stomach. Since 
then, expression of VGLUTs has been confirmed in the peripheral 
projections of vagal and DRG neurons innervating the gut of guinea pig, rat 
and mouse (see 9 and references therein). More recently, we showed that 
over 95% of mouse colorectal DRG neurons express VGLUT2, and in a much 
lower proportion, VGLUT1 9. Similarly, we demonstrate in the present study 
that mouse urinary bladder DRG neurons also predominantly express 
VGLUT2, and to a lesser extent VGLUT1 or VGLUT3. 
The urinary bladder, like the colorectum, is innervated by lumbar 
splanchnic and pelvic nerves, with cell bodies in TL and LS DRGs, respectively. 
We found that urinary bladder sensory neurons expressing VGLUT1 or VGLUT3, 
unlike those synthesizing VGLUT2, are more abundant in TL than in LS DRGs. An 
increasing number of reports reveal significant differences in both the functions 
and neurochemical expression of various molecules in afferent neurons 
comprising the two pathways of innervation (see 5 and references therein). For 
example, 66% of mouse TL bladder neurons express the transient receptor 
potential cation channel, subfamily A, member 1 (TRPA1) mRNA, whereas TRPA1 
expression in LS bladder neurons is scarce (~2.5%) 14. In contrast, TH is 
expressed in threefold (colorectum) and fivefold (urinary bladder) greater 
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proportions in LS DRGs 5. The differences in expression of VGLUT1 and VGLUT3 
between TL and LS bladder neurons reported here could imply differences in 
neuronal physiology. This has already been shown in the mouse colorectum, 
where a higher expression of transient receptor potential cation channel, subfamily 
V, member 1 (TRPV1) in TL than in LS DRGs corresponds with a stronger 
response to applied capsaicin in colorectal TL nerve terminals 15. 
We found that of the 94% of retrogradely traced urinary bladder DRG 
neurons expressing VGLUT2, about half coexpressed the peptidergic marker 
CGRP. These figures correlate with previous studies in rat showing that up to 69% 
of DRG neurons innervating the urinary bladder express CGRP (see 4). In the 
mouse colorectum, more than 80% of all retrogradely traced DRG neurons 
coexpressed VGLUT2 and CGRP 9, in accordance with the expression of CGRP in 
the vast majority of DRG neurons innervating the rodent colorectum (see 4). 
Accordingly, it can be concluded that a large proportion of visceral glutamatergic 
sensory neurons also synthesize, and potentially co-release, CGRP. In contrast, in 
DRGs innervating non-visceral tissues only ~31% of the ~65% VGLUT2-IR 
neurons colocalize CGRP 8, suggesting potentially variable levels of co-release of 
glutamate and CGRP between DRG neurons innervating different tissues. 
VGLUT1 and VGLUT3-IR urinary bladder neurons did not coexpress 
CGRP. However, since virtually all neurons innervating this organ synthesized 
VGLUT2, it is highly likely that VGLUT1 and/or VGLUT3 are coexpressed with 
VGLUT2 in its non-peptidergic subpopulation (see above). Coexpression of more 
than one type of VGLUT was first shown for some neurons in the central nervous 
system 16, and later confirmed for VGLUT1 and VGLUT2 in non-visceral primary 
afferent neurons and their projections (see 8 and references therein). Our studies 
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in mouse colorectum 9 and urinary bladder (current study) further support the 
supplementary contribution of different VGLUTs in glutamatergic physiology in 
sensory neurons. 
TRPV1 is a non-selective cation channel activated by pH, heat and 
capsaicin and strongly implicated in urinary bladder nociception (see 17). TRPV1 is 
expressed in many peptidergic urinary bladder DRG neurons in both rat 18 and 
mouse 14,15,18. Considering the prominent expression of VGLUT2 in peptidergic 
urinary bladder DRG neurons, VGLUT2 undoubtedly coexists with TRPV1. In 
support, coexpression of VGLUT2 with TRPV1 has been previously demonstrated 
in nerve fibers terminating in the mouse rectum 19. Interestingly, TRPV1 and 
glutamate receptors (GluRs) also colocalize in non-visceral small diameter primary 
afferent neurons, and it has been shown that the induction of c-Fos expression in 
the spinal dorsal horn induced by subcutaneous injection of capsaicin is prevented 
by concomitant subcutaneous administration of ionotropic or metabotropic 
glutamatergic receptor antagonists 20. Peripheral release of glutamate, likely from 
primary afferent nerve terminals, has been demonstrated in the hindpaw skin of 
rats exposed to intraplantar injection of the irritant formalin (see 21 and references 
therein). Moreover, the local injection of glutamate induces nociceptive behaviors 
both in rats 22 and humans 23. Thus, it could be speculated that a TRPV1-glutamate 
receptor interaction, both at central as well as peripheral nerve terminals, and 
potentially driven by glutamate released from primary afferent neurons, could have 
a role in the physiopathology of sensation and pain of the urinary bladder. 
As suggested above, urinary bladder nociception could be influenced 
by the peripheral release and action of glutamate. In recent years, botulinum toxin 
A has been used in the treatment of urinary bladder pain associated with interstitial 
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cystitis. Although originally described as a potent inhibitor of acetylcholine release 
in the neuromuscular junction (see 24), it is increasingly accepted that botulinum 
toxin A also blocks transmitter release at non-acetylcholinergic synapses. Thus, it 
has been hypothesized that botulinum toxin A desensitizes peripheral afferent 
nerves by inhibition of the vesicular release of ATP, as well as the release of 
peptides such as CGRP and SP. Reduction of the axonal expression of TRPV1 
from urothelial and suburothelial nerve endings has also been proposed (see 25 
and references therein). In humans, the synaptic vesicle protein 2, a high-affinity 
receptor for botulinum toxin A, and the synaptosomal-associated protein 25 
(SNAP-25), one of the SNAP (Soluble NSF-attachement Proteins) receptors 
(SNAREs) involved in vesicle fusion prior to neurotransmitter release and essential 
for the blocking action of botulinum toxin A, have been found in at least half of the 
peptidergic nerve fibers present in the urinary bladder 26. In rodents, most of the 
non-visceral 8, colorectal 9 and urinary bladder (present study) DRG 
neurons/nerves expressing VGLUT2, and often synthesizing peptides, are most 
likely provided with the SNARE machinery for synaptic neurotransmitter release. 
Therefore, it can be speculated that in these neurons/nerves, botulinum toxin A 
could also affect the docking of glutamatergic synaptic vesicles, limiting the 
release of glutamate, and thus contributing to the analgesic effects of the toxin. In 
fact, the benefits of using botulinum toxin have already been successfully explored 
in animals with non-visceral neuropathy 24. 
Finally, we also detected a few MPG neurons projecting to the urinary 
bladder that also expressed VGLUT2, whereas none of the retrogradely traced 
neurons in the LSC showed positive immunostaining for any VGLUT. Thus, in 
normal conditions, not only DRGs, but also the MPG may be a source of VGLUT2 
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immunoreactive fibers in the urinary bladder. Interestingly, we have recently shown 
that upon injury of the pelvic nerve, a subpopulation of LSC neurons upregulates 
VGLUT2 10. In that study, we did not trace the neurons, and thus it remains to be 
established if some of the LSC neurons upregulating VGLUT2 projected either to 
the urinary bladder or the colorectum. Likewise, it could be speculated that MPG 
neurons, either projecting to visceral organs or not, may upregulate VGLUT2 after 
injury of their postganglionic axons. 
In conclusion, we present an immunohistochemical account of 
the expression of VGLUTs in sensory and autonomic neurons innervating 
the mouse urinary bladder. The finding of a preponderant expression of 
VGLUT2, as recently also demonstrated in the mouse colorectum 9, suggests 
a relevant role for this transporter in glutamatergic neurotransmission in 
neurons innervating pelvic visceral organs, from which the principal 
conscious sensations that arise are discomfort and pain. Glutamate, which 
is cointained in the central terminals of primary afferents, spinal 
interneurons and terminals of fibers that descend from the medulla 
oblongata 27, is well established as important to nociceptive transmission 
from pelvic organs 1,28. Thus, a complex interaction between spinal 
ionotropic (NMDA and AMPA) receptors has been shown in the spinal 
processing of nociceptive input from the irritated lower urinary tract (LUT) 29. 
Likewise, a facilitatory role in urinary bladder primary afferent processing 
has been ascribed to the metabotropic receptor mGluR5, both in normal 
conditions as well as during inflammation of the LUT 28. However, it should 
be noted that the role of peripheral glutamate release in the urinary bladder 
is unclear. Thus, the intravesical application of metabotropic glutamate 
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receptor antagonists has no effect on urinary bladder contractility and pelvic 
nerve afferent firing in normal rats 30. Studies using animal disease models 
will be necessary to establish the potential involvement of peripheral 
glutamate/glutamatergic receptors in the urinary bladder.
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Figure legends 
Table 1. Technical specifications of the primary and secondary antibodies, and 
fluorophores used in this study. 
 
Table 2. Percentages of thoracolumbar (TL) or lumbosacral (LS) DRG urinary 
bladder NPs expressing VGLUT1, VGLUT2 or VGLUT3. Combined TL and LS data 
are also shown. *P<0.05; ***P<0.001. 
 
Figure 1. Expression of VGLUTs in DRGs innervating the urinary bladder. 
Optical immunofluorescence photomicrographs of sections of S1 (A-C), L6 
(D-F), T10 (G-I) or T11 (J-L) DRGs incubated with VGLUT1 (B), VGLUT2 (E, H) 
or eGFP-VGLUT3 (K) antisera. In the merged panels (C, F, I, L), retrogradely 
labeled urinary bladder DRG neurons containing FB (A, D, G, J) are shown in 
purple; VGLUT1-, VGLUT2- or eGFP-VGLUT3-IR neurons are shown in green; 
colocalizations are shown in white (VGLUT+FB). Double arrowheads in 
panels A-C, D-I or J-L show VGLUT1-, VGLUT2 or eGFP-VGLUT3-IR urinary 
bladder NPs, respectively. Arrows in panels A, G or J show urinary bladder 
NPs lacking VGLUT1, VGLUT2 or eGFP-VGLUT3-Li, respectively. Arrowheads 
in panels B, E or K show non-traced NPs expressing VGLUT1, VGLUT2 or 
eGFP-VGLUT3. Scale bars: 50 μm (I=G, H; L=A-F, J-K). 
 
Figure 2. Patterns of co-expression of VGLUTs with CGRP in DRGs 
innervating the urinary bladder. Optical immunofluorescence 
photomicrographs of sections of T10 (A-D), L6 (E-H) or S2 (I-L) DRGs 
incubated with VGLUT1 (B), VGLUT2 (F) or eGFP-VGLUT3 (J) antisera. In the 
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merged panels (D, H, L), retrogradely labeled urinary bladder DRG neurons 
containing FB (A, E, I) are shown in red; VGLUT1-, VGLUT2- or eGFP-VGLUT3-
IR neurons are shown in green; CGRP-IR neurons are shown in blue; 
colocalizations are shown in white (VGLUT+FB+CGRP), orange (VGLUT-FB) 
or purple (CGRP+FB). White double arrowheads in panels A-D, E-H or I-L 
show VGLUT1- VGLUT2- or eGFP-VGLUT3-IR urinary bladder NPs lacking 
CGRP-Li, respectively. Black double arrowheads in panels A-D or I-L show 
urinary bladder NPs expressing CGRP and lacking VGLUTs-Li. Double 
arrows in panels E-H show VGLUT2-IR urinary bladder NPs coexpressing 
CGRP. White arrowheads in panels B, F or J show non-traced VGLUT1- 
VGLUT2 or eGFP-VGLUT3-IR DRG NPs lacking CGRP-Li, respectively. Black 
arrowheads in panels E-H show non-traced VGLUT2-IR NPs coexpressing 
CGRP. Scale bar: 50 μm (L=A-K). 
 
Figure 3. Expression of VGLUTs in LSCs and MPGs innervating the urinary 
bladder. Optical (A, D, G, J, M, P) and confocal (B, C, E, F, H, I, K, L, N, O, Q, 
R) immunofluorescence photomicrographs of sections of the LSC (A-F) and 
the MPG (G-R) after incubation with VGLUT1 (B, H) or VGLUT2 (E, K, N, Q) 
antisera. In the merged panels (C, F, I, L, O, R), retrogradely labeled urinary 
bladder DRG neurons containing FB (A, D, G, J, M, P) are shown in purple; 
VGLUT1- or VGLUT2-IR neurons are shown in green; colocalizations are 
shown in white (VGLUT+FB). Arrows in panels A and G, or in D, J and P 
show urinary bladder NPs in the LSC (A, D) or the MPG (G, J, P) lacking 
VGLUT1- or VGLUT2-Li, respectively. White arrowheads in panels H or E, K 
and Q show VGLUT1- or VGLUT2-IR varicosities in the LSC (E) or the MPG (H, 
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K, Q), respectively (white arrowhead in panel H is shown at higher 
magnification in I). Black arrowheads in E, K and Q show VGLUT2-IR fibers in 
the LSC (E) or the MPG (K, Q). VGLUT2-IR varicosities surrounding urinary 
bladder NPs lacking the transporter are detected (combined arrow and white 
arrowhead in F, also shown in inset in F). Double arrows in panels J-L show 
VGLUT2-IR urinary bladder NPs (shown at higher magnification in M-O). 
White double arrowhead in panel Q shows a VGLUT2-IR basket surrounding 
non-traced NPs lacking the transporter (also shown in inset in R).  Scale 
bars: 50 μm (L=A-K; O=M, N; R=P, Q); 10 μm (all insets). 
 
Figure 4. Confocal immunofluorescence photomicrographs of transverse (A-
D) and sagittal (E-G) sections of the urinary bladder dome (A-D), trigone (E) 
and urethra (F, G), after incubation with VGLUT1 (A, B) or VGLUT2 (C-G) 
antiserum. White double arrowheads in panels A and B, or C and D show 
VGLUT1- or VGLUT2-IR nerve fibers in the muscular layer of the urinary 
bladder, respectively. White arrowheads in panels B, or C and D show 
VGLUT1- or VGLUT2-IR nerve fibers in the submucosal layer of the urinary 
bladder, respectively. Arrows in panel E show VGLUT2-IR nerve fibers in the 
urinary bladder trigone. Black arrowheads in panels F and G show VGLUT2-
IR fibers penetrating the urethra. White arrowheads in panels F and G show 
VGLUT2-IR nerve fibers innervating the urethra. Scale Bars: 100 μm (D=A-C; 
E; G=F). 
 
Figure 5. Confocal immunofluorescence photomicrographs of transverse 
sections of the urinary bladder after co-incubation with VGLUT1 (A) or 
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VGLUT2 (D, G, J) and CGRP (B, E, H, K) antisera. In the merged panels (C, F, 
I, L), VGLUT1- or VGLUT2-IR fibers are shown in green; CGRP-IR fibers are 
shown in purple; colocalizations are shown in white (VGLUT+CGRP). 
Arrowheads in panels A, or D and J show VGLUT1- or VGLUT2-IR nerve fibers 
lacking CGRP-Li in the urinary bladder dome, respectively. Arrows in B and 
H show CGRP-IR nerve fibers lacking VGLUTs-Li in the muscular layer of the 
urinary bladder dome. Double arrows in panels G-I or J-L show VGLUT2- and 
CGRP-IR nerve fibers in the mucosal (inset 1 in F, shown at higher 
magnification in G-I) and muscular layers (inset 2 in F, shown at higher 
magnification in J-L) of the urinary bladder, respectively. Scale bars: 50 µm 
(F=D, E), 25 µm (C=A, B; I=G, H; L=J, K).
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PRIMARY ANTIBODIES
Target antigen and host species Dilution Reference or source
Rabbit anti-VGLUT1 1:4,000 (T) Kawamura et al., 2006
Guinea Pig anti-VGLUT2 1:8,000 (T)
Miyazaki et al., 2003; Brumovsky et al., 
2007; 2011a, b
Rabbit anti-EGFP 1:4,000 A11122; Molecular Probes
Rabbit anti-CGRP 1:8,000 (I) / 1:40,000 (C;T) C8198; Sigma
SECONDARY ANTIBODIES/FLUOROPHORES
HRP-donkey anti-guinea pig 1:200 713-035-003; Jackson Immunoresearch
HRP-donkey anti-rabbit 1:200 711-035-152; Jackson Immunoresearch
TRITC-donkey anti-rabbit 1:400 711-025-152; Jackson Immunoresearch
Fluorescein tyramide 1:700 NEL741; Perkin Elmer
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